With the future of mRNA vaccines secure, an expert discusses the benefits of vaccine platform diversification.

The new plant will allow the company to execute end-to-end clinical- and commercial-stage production of its mRNA medicines.

Moderna, Inc. (MRNA) on Wednesday announced that it will bring drug product manufacturing to its existing Moderna Technology ...

Moderna (MRNA) stock is in focus as the company completes U.S. mRNA production network, investing $140M in Massachusetts and ...

New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network ...

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee ...

Analysts also weigh in on Chesapeake Utilities, Halozyme Therapeutics, Sea Ltd., and Roper Technologies. Trump reverses on tariffs for some imports, Bitcoin falls on details of strategic reserve, ...

Moderna’s third quarter was shaped by sharply lower demand for COVID-19 vaccines, yet the company delivered results above ...

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected revenue range to $1.6 – $2.0 billion Improves 2025 expected GAAP operating ...

Biotechnology company Moderna (NASDAQ:MRNA) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell ...

Q3 2025 Management View Stéphane Bancel, CEO, reported third quarter revenue of $1 billion, driven by sales of fully approved vaccines including Spikevax, mNEXSPIKE, and mRESVIA, and announced a net ...